ICER finds blue­bird's po­ten­tial $2.1M gene ther­a­py cost-ef­fec­tive as FDA ad­comm sched­uled for June

The cost-ef­fec­tive­ness watch­dog ICER said Wednes­day that blue­bird’s po­ten­tial gene ther­a­py for a rare blood dis­or­der — which goes be­fore an FDA ad­comm in June …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER